Breye Therapeutics strengthens management team

Danish clinical-stage retinal diseases biotech Breye Therapeutics today announced the appointment of Peter Adamson as chief scientific Officer (CSO).

Dr Adamson has over 20 years of experience in ophthalmology drug development. He has previously held senior leadership positions at various biopharmaceutical companies including vice president and head of ophthalmology research at UK pharma major GSK (LSE: GSK), where he generated multiple clinical candidates and acted as lead biologist on a number of discovery programs. He previously also worked at ProQR and recently Tenpoint Therapeutics, where he was involved in building pipelines and securing successful financing.

Additionally, Breye has name Gabriela Burian as a new member of its board of directors.